Synergism of colistin and globular endolysins against multidrug-resistant gram-negative bacteria

被引:0
|
作者
Zhang, Pengfei [1 ]
Zeng, Ping [1 ]
Lai, Christopher K. C. [2 ]
Ip, Margaret [2 ]
To, Kenneth K. W. [1 ]
Zuo, Zhong [1 ]
Xia, Jiang [3 ]
Leung, Sharon S. Y. [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Chem, Hong Kong, Peoples R China
关键词
Endolysin; Colistin; Gram-negative bacteria; ACINETOBACTER-BAUMANNII; BIOFILM FORMATION; MECHANISMS;
D O I
10.1016/j.ijbiomac.2024.134670
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endolysins (lysins), a novel class of antibacterial agents derived from bacteriophages, efficiently lyse bacteria by degrading the peptidoglycan layer within the bacterial wall. Colistin, a classic peptide antibiotic with the ability to permeabilize the outer membrane, has recently shown great promise in synergizing with lysins against gramnegative bacteria. However, the exact mechanisms responsible for their synergy remain unclear. Here, we first demonstrated the synergistic bacterial killing of various lysin and colistin combinations. With a model lysin, LysAB2, we then confirmed that there is a threshold concentration of colistin causing sufficient permeabilization of the outer membrane for lysin to access the peptidoglycan layer and subsequently exert its lytic ability. The threshold colistin concentrations were found to range 0.2-0.8 mu M for the tested bacteria, with the exact value largely depending on the density of lipopolysaccharides on the outer membrane. Beyond the threshold colistin level, LysAB2 could synergize with colistin at a concentration as low as 0.31 mu M. Next, we proved for the first time that lysin-induced degradation of the peptidoglycan layer facilitated the disruption of cytoplasmic membrane by colistin, elevated the level of reactive oxygen species in bacterial cells, and boosted the killing effect of colistin. Additionally, the colistin-lysin combination could effectively eliminate established biofilms due to the biofilm dispersal ability of lysin. The in-vivo efficacy was preliminary confirmed in a Galleria mellonella infection model for combination with colistin doses (>= 1.8 mu g/larvae), which could reach beyond the threshold concentration, and a fixed LysAB2 dose (10 mu g/larvae). In summary, our study provided the first experimental evidence unravelling the mechanisms behind the synergy of colistin and lysins. All these findings provided important insights in guiding the dosing strategy for applying this combination in future development.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria
    Zhu, Chongyu
    Schneider, Elena K.
    Wang, Jiping
    Kempe, Kristian
    Wilson, Paul
    Velkov, Tony
    Li, Jian
    Davis, Thomas P.
    Whittaker, Michael R.
    Haddleton, David M.
    JOURNAL OF CONTROLLED RELEASE, 2017, 259 : 83 - 91
  • [22] Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens
    Kadouri, Daniel E.
    To, Kevin
    Shanks, Robert M. Q.
    Doi, Yohei
    PLOS ONE, 2013, 8 (05):
  • [23] An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria
    Alysha G. Elliott
    Johnny X. Huang
    Søren Neve
    Johannes Zuegg
    Ingrid A. Edwards
    Amy K. Cain
    Christine J. Boinett
    Lars Barquist
    Carina Vingsbo Lundberg
    Jason Steen
    Mark S. Butler
    Mehdi Mobli
    Kaela M. Porter
    Mark A. T. Blaskovich
    Sergio Lociuro
    Magnus Strandh
    Matthew A. Cooper
    Nature Communications, 11
  • [24] Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria
    Ong'uti, Sharon
    Czech, Mary
    Robilotti, Elizabeth
    Holubar, Marisa
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (07) : 1303 - 1312
  • [25] An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria
    Elliott, Alysha G.
    Huang, Johnny X.
    Neve, Soren
    Zuegg, Johannes
    Edwards, Ingrid A.
    Cain, Amy K.
    Boinett, Christine J.
    Barquist, Lars
    Lundberg, Carina Vingsbo
    Steen, Jason
    Butler, Mark S.
    Mobli, Mehdi
    Porter, Kaela M.
    Blaskovich, Mark A. T.
    Lociuro, Sergio
    Strandh, Magnus
    Cooper, Matthew A.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [26] An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria
    Yusuf, Erlangga
    Bax, Hannelore I.
    Verkaik, Nelianne J.
    van Westreenen, Mireille
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 22
  • [27] Assessment of Colistin Treatment in Multidrug-Resistant Gram-Negative Bacterial Infections
    Coskun, Belgin
    Azap, Alpay
    Yilmaz, Gulden
    Ayhan, Muge
    Saricaoglu, Elif Mukime
    KLIMIK JOURNAL, 2020, 33 (02) : 142 - 147
  • [28] In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria
    Chitnis, S.
    Chitnis, V.
    Chitnis, D. S.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (02) : 226 - 229
  • [29] New Antibiotics for the Treatment of multidrug-resistant gram-negative Bacteria
    Probst-Kepper, Michael
    Geginat, Gernot
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2018, 53 (7-8): : 529 - 542
  • [30] MRGN: new classification for multidrug-resistant Gram-negative bacteria
    Kaase, Martin
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2013, 37 (06): : 299 - 304